drugset

drugset / Trial / NCT00461617

Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients

NCT00461617 ↗

Phase 3 Completed 291 enrolled Kissei Pharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.

Timeline

Start: 2006-08
Primary completion: 2007-07
Completion: 2007-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Mitiglinide	Small molecule	10 mg	—

Indications